home / stock / crnx / crnx news

CRNX News and Press, Crinetics Pharmaceuticals Inc. From 11/08/21

Stock Information
Company Name: Crinetics Pharmaceuticals Inc.
Stock Symbol: CRNX
Market: NASDAQ
Website: crinetics.com
Menu
CRNX CRNX Quote CRNX Short CRNX News CRNX Articles CRNX Message Board
Get CRNX Alerts

News, Short Squeeze, Breakout and More Instantly...
CRNX - Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress

SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced toda...
CRNX - Shares of Crinetics Pharmaceuticals Inc. (CRNX) Rise Above Previous 52-Week High

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) traded today at a new 52-week high of $27.91. So far today approximately 223,000 shares have been exchanged, as compared to an average 30-day volume of 297,000 shares. Over the past year, Crinetics Pharmaceuticals Inc. has traded in a range of...

CRNX - Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

– Pipeline Includes Three New Chemical Entities with Clinical Proof-of-concept Following CRN04894 and CRN04777 Phase 1 Readouts – – Advancing a Parathyroid Hormone Receptor Antagonist Program Using the Drug Development Blueprint Followed by Paltusotine, CRN0...

CRNX - Shares of Crinetics Pharmaceuticals Inc. (CRNX) Have Risen Above Previous 52-Week High

Shares of Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) traded today at $27.57, eclipsing its 52-week high. So far today approximately 223,000 shares have been exchanged, as compared to an average 30-day volume of 300,000 shares. Crinetics Pharmaceuticals Inc. share prices have moved betw...
CRNX - Shares of Crinetics Pharmaceuticals Inc. (CRNX) Rise to a New 52-Week High

Shares of Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) traded today at $25.90, eclipsing its 52-week high. This new high was reached on approximately average trading volume as 223,000 shares traded hands, while the average 30-day volume is approximately 293,000 shares. Over the past year...

CRNX - Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced toda...

CRNX - Radionetics Oncology Emerges from Crinetics Pharmaceuticals with a Platform and Deep Pipeline of Nonpeptide Targeted Radiopharmaceutical Drug Candidates for Precision Oncology

Co-founded by Crinetics, 5AM Ventures and Frazier Healthcare Partners, the New Company Launches with $30M in Initial Financing Provided by 5AM and Frazier Pipeline is Built from Crinetics’ Core Nonpeptide Platform and Includes Drug Candidates and Leads Against 10 Oncology...
CRNX - Crinetics Pharmaceuticals to Unveil its Parathyroid Hormone Receptor Antagonist Program at the American Society for Bone and Mineral Research Annual Meeting

- Late-breaking Poster Presentation on Sunday, October 3, 2021 SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics...

CRNX - Crinetics Pharmaceuticals' Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study

CRN04777 Phase 1 Program Progressing to Multiple Ascending Dose Cohorts to Advance Development as a Treatment for Congenital Hyperinsulinisms Demonstrated Dose-dependent Reductions in Glucose-stimulated and Sulfonylurea-induced Insulin Secretion Management Hosting Webcas...

CRNX - Crinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Officer

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc . (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today a...
Previous 10 Next 10